Propofol

Eagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

Retrieved on: 
Wednesday, November 16, 2022
Hypertension, Bradycardia, Ventilation, Itch, Hypoxia, Hypoventilation, Colonoscopy, Rash, GABA, Flumazenil, History, Placenta, Liver, III, Breast milk, Analgesic, ASA, Obstructive sleep apnea, Brain, Life, Safety, Patient, Apnea, Anaphylaxis, NMDA, Vital signs, Airway obstruction, Anesthesia, Maintenance, Benzodiazepine, Propofol, Hives, CNS, Patent, Government budget balance, CIV, Confusion, Systolic hypertension, Lethargy, Death, Hypotension, Hypotonia, IV, Human, Pregnancy, Bronchoscopy, Coma, Dentistry, Liquor, Pharmaceutical industry

WOODCLIFF LAKE, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the following speakers and world-renowned Key Opinion Leaders will be featured at the Company’s Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel, at 8:00am ET:

Key Points: 
  • Resuscitative drugs, and age- and size-appropriate equipment for bag-valve-maskassisted ventilation must be immediately available during administration of BYFAVO.
  • Concomitant use of benzodiazepines, including BYFAVO, and opioid analgesics may result in profound sedation, respiratory depression, coma, and death.
  • The sedative effect of intravenous BYFAVO can be accentuated by concomitantly administered CNS depressant medications, including other benzodiazepines and propofol.
  • BYFAVO is contraindicated in patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40.

Kit Check Partners with Genixus™ to Introduce RFID-Tagged Propofol as the First Product Within the KinetiX™ Line of Ready-to-Administer Syringes

Retrieved on: 
Wednesday, August 31, 2022
Pharmaceutical, General Health, Health, FDA, Artificial Intelligence, Technology, Supply Chain Management, Retail, Medication, Doctor of Pharmacy, Solution, RTA, LinkedIn, Propofol, Senior, NDC, RFID, Hospital, Refrigeration, Kinetix, FDA, Syringe, Patient, Medicine, Medical device

Medications labeled with RFID tags at the manufacturer level helps ensure item-level visibility of drug products throughout their dynamic lifecycle.

Key Points: 
  • Medications labeled with RFID tags at the manufacturer level helps ensure item-level visibility of drug products throughout their dynamic lifecycle.
  • As a result, there are a variety of favorable outcomes including notably heightened workflow efficiency, decreased spending and streamlined inventory for hospitals.
  • RFID tags record data for each dose such as lot number, national drug code (NDC), and refrigeration date.
  • To date, our more than 1,000 U.S. and Canadian hospital partners have adopted Kit Check solutions to solve the most challenging of healthcare problems.

Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, August 30, 2022
Systolic hypertension, Government budget balance, Human, Safety, Flumazenil, CIV, Propofol, IV, Brain, Colonoscopy, Ventilation, Death, ASA, Obstructive sleep apnea, Placenta, Maintenance, Bradycardia, Airway obstruction, Vital signs, Hives, Itch, Rash, Bronchoscopy, Liver, GABA, Patent, Analgesic, Anaphylaxis, Hypotonia, Breast milk, Apnea, History, Hypertension, Anesthesia, Confusion, III, Pregnancy, Hypotension, Hypoventilation, Hypoxia, Lethargy, Benzodiazepine, Coma, CNS, Life, NMDA, Patient, Dentistry, Liquor, Pharmaceutical industry

Resuscitative drugs, and age- and size-appropriate equipment for bag-valve-maskassisted ventilation must be immediately available during administration of BYFAVO.

Key Points: 
  • Resuscitative drugs, and age- and size-appropriate equipment for bag-valve-maskassisted ventilation must be immediately available during administration of BYFAVO.
  • Concomitant use of benzodiazepines, including BYFAVO, and opioid analgesics may result in profound sedation, respiratory depression, coma, and death.
  • The sedative effect of intravenous BYFAVO can be accentuated by concomitantly administered CNS depressant medications, including other benzodiazepines and propofol.
  • BYFAVO is contraindicated in patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40.

Genixus™ Introduces Propofol as the First Product to be Delivered Within KinetiX™ Ready-to-Administer (RTA) Syringe Platform

Retrieved on: 
Tuesday, August 9, 2022
Workflow, OR, Conference, RTA, Kinetix, Bedside, Medicine, Propofol

LAS VEGAS, Aug. 9, 2022 /PRNewswire/ -- Genixus™, a pharmaceutical company focused on transforming acute and critical care medicines, today announced that it will offer Propofol as the first product within its KinetiX™ platform of RTA syringe products at the Annual National Pharmacy Purchasing Association Conference (booth # 603-605). 

Key Points: 
  • "Following the recent 503B registration and licensing of our facility in North Carolina, Genixus is excited to deliver an RTA format of Propofol, one of the most commonly used medications within the OR setting" said Seth Coombs , Co-Founder & Chief Commercial Officer of Genixus.
  • "Our KinetiX platform is designed to deliver clinical tools that seamlessly integrate intothe operations of the acute and critical care setting, allowing clinicians to focus on their ultimate goal: the quality of care and patient outcomes."
  • The new Propofol Syringe is the first product to be available within the KinetiX RTA platform, which is designed to simplify workflow and support effective care delivery.
  • To support error resistance and clinical efficiency, KinetiX Propofol features several key attributes:

Eagle Pharmaceuticals to Host Second Quarter 2022 Financial Results on August 9, 2022

Retrieved on: 
Thursday, July 28, 2022
Death, Anesthesia, Hypoventilation, Brain, Government budget balance, Colonoscopy, III, IV, NMDA, Itch, Human, Anaphylaxis, Maintenance, History, GABA, Flumazenil, CIV, Ventilation, Bronchoscopy, Patent, CNS, Safety, Hypotension, Obstructive sleep apnea, Benzodiazepine, Pregnancy, Rash, ASA, Vital signs, Apnea, Coma, Confusion, Lethargy, Placenta, Systolic hypertension, Patient, Airway obstruction, Bradycardia, Life, Analgesic, Hypertension, Liver, Hives, Breast milk, Propofol, Hypotonia, Hypoxia, Dentistry, Liquor, Pharmaceutical industry

Resuscitative drugs, and age- and size-appropriate equipment for bag-valve-maskassisted ventilation must be immediately available during administration of BYFAVO.

Key Points: 
  • Resuscitative drugs, and age- and size-appropriate equipment for bag-valve-maskassisted ventilation must be immediately available during administration of BYFAVO.
  • Concomitant use of benzodiazepines, including BYFAVO, and opioid analgesics may result in profound sedation, respiratory depression, coma, and death.
  • The sedative effect of intravenous BYFAVO can be accentuated by concomitantly administered CNS depressant medications, including other benzodiazepines and propofol.
  • BYFAVO is contraindicated in patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40.

Global Artificial Coma/Medically Induced Coma Market Forecast to 2030: Focus on Drug Type, Application and Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 27, 2022
Health, General Health, Pfizer, Propofol, Laboratory, Stroke, CAGR, Pharmacy, Status epilepticus, Piramal Group, Environment, Viatris, Traumatic brain injury, Hikma Pharmaceuticals, Drug overdose, AstraZeneca, Coma, Pharmaceutical industry

The global artificial coma/medically induced coma market was valued at $640.17 million in 2020, and is projected to reach $868.63 million by 2030, registering a CAGR of 3.1%.

Key Points: 
  • The global artificial coma/medically induced coma market was valued at $640.17 million in 2020, and is projected to reach $868.63 million by 2030, registering a CAGR of 3.1%.
  • The global artificial coma/medically induced coma market is segmented on the basis of drug type, application, distribution channel, and region.
  • By application, the market is fragmented into status epilepticus, stroke, traumatic brain injury, brain infections, drug overdose, and others.
  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global artificial coma/medically induced coma market to identify the prevailing opportunities.

DoseData Launches Real-time Analytics on 315 Drugs to Provide More Transparency Into the Pharmaceutical Supply Chain

Retrieved on: 
Monday, April 25, 2022
Other Manufacturing, Technology, Hospitals, Manufacturing, Health, Pharmaceutical, Retail, Data Management, Supply Chain Management, Glycopyrronium bromide, Decision-making, Gaps, Lidocaine, Marketing, EMR, VP, Anecdote, VP/CSS, Hospital, Organization, Dataproducts, Bed, Forecasting, Data visualization, Intelligence, Multimedia, Industry, Pharmaceutical industry, Risk management, Propofol

Until now, no datasets on the market have offered insight into this crucial part of the pharmaceutical supply chain.

Key Points: 
  • Until now, no datasets on the market have offered insight into this crucial part of the pharmaceutical supply chain.
  • Because DoseData sources information directly from hospitals, the company is able to provide daily updates regarding all relevant data.
  • By relying solely on months-old sales data, pharmaceutical companies have historically been looking in the rearview as they try to navigate an ever-changing and unpredictable supply chain.
  • Were thrilled to bring DoseData to the market and offer unparalleled transparency to the healthcare and pharmaceutical ecosystem, said Tara Hanusa, Data Product Manager at DoseData.

ANALYSIS: GPOs Helped Increase Domestic Manufacturing Capacity, Protected Hospitals and Patients from Thousands of Fraudulent Sellers, and Helped Identify and Bring New Suppliers to Market to Avert Supply and Drug Shortages During COVID-19

Retrieved on: 
Wednesday, April 20, 2022
Patient, Propofol, COVID-19, N95 respirator, N95, Steel, Hospital, Organization, Occupational safety and health, Time-invariant system, Contract, Caregiver, Essential Products, NIOSH, GPO, National Institute, National Institute for Occupational Safety and Health, Health care, Acıbadem Healthcare Group, Nursing, FDA, HSCA, Medicare, Pharmaceutical industry, Personal protective equipment, Health, Medicaid

WASHINGTON, April 20, 2022 /PRNewswire/ -- The Healthcare Supply Chain Association (HSCA), which represents the nation's leading healthcare group purchasing organizations (GPOs), today released an analysis of key learnings, best practices, and case studies on the role of GPOs in the response to the COVID-19 pandemic. The issue brief, "Healthcare Group Purchasing Organizations: Critical Partners in the COVID-19 Response Effort," highlights specific ways in which GPOs were able to shore up domestic manufacturing and help new suppliers come to market, communicate about anticipated demand surge to allow manufacturers to increase capacity, avert supply and drug shortages, and protect healthcare providers and patients from counterfeit or inferior medical products.

Key Points: 
  • "Healthcare group purchasing organizations have long helped avert drug shortages and safeguard access to essential medical supplies, a role that has become even more important during the COVID-19 pandemic.
  • Specific finings and best practices about the ways in which GPOs helped healthcare stakeholders navigate the COVID-19 pandemic included:
    Demand Surge Notices Led to Increased Manufacturer Capacity.
  • Multiple GPOs launched programs aimed at increasing supply chain resiliency and redundancy to prevent shortages of critical products.
  • One GPO vetted thousands of potential gray market suppliers and found that more than 90% were illegitimate.

Avet Pharmaceuticals Announces Approval and Launch of Propofol Injectable Emulsion, USP

Retrieved on: 
Thursday, April 7, 2022
Company, Sale, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Marketing, MAC, Growth, Multimedia, Patient, Propofol, USP, Food and Drug Administration, Hospital, Food, Pain management, View, LLC, AB, News, ICU, Maintenance, FDA, Acquisition, Pharmaceutical industry, Avet

EAST BRUNSWICK, N.J., April 7, 2022 /PRNewswire/ -- Avet Pharmaceuticals Inc. announced today the U.S. launch of its Propofol Injectable Emulsion, USP 10 mg/mL, in 20, 50 and 100 ml Single Patient-Use Vials, an AB rated generic equivalent of DIPRIVAN® (propofol) Injectable Emulsion USP, following its abbreviated new drug application approval from the Food and Drug Administration (FDA). The Company will commence distribution immediately.

Key Points: 
  • EAST BRUNSWICK, N.J., April 7, 2022 /PRNewswire/ --Avet Pharmaceuticals Inc. announced today the U.S. launch of its Propofol Injectable Emulsion, USP 10 mg/mL, in 20, 50 and 100 ml Single Patient-Use Vials, an AB rated generic equivalent of DIPRIVAN(propofol) Injectable Emulsion USP, following its abbreviated new drug application approval from the Food and Drug Administration (FDA).
  • Avet Pharma Announces Approval and Launch of Propofol Injectable Emulsion, USP to address current market shortage
    "The approval of Avet's generic propofol injectable emulsion is welcome news to our team, who are prepared to deliver with urgency this much-needed therapy to hospitals and surgical centers, where the product has been in short supply," said Marvin Samson, Chairman of Avet Pharmaceuticals.
  • "At Avet, we are committed to delivering high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions.
  • Today's approval announcement is our most recent example of fulfilling that commitment and will serve as an important growth driver for our Company."

United States Anesthesia Drugs Market, Size, Forecast Report 2022-2027: Industry Trends, Share, Growth, Impact of COVID-19, Opportunities, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 9, 2022
Health, Pharmaceutical, Policy, Blue Shield, Hypokinesia, Anesthetic, Isoflurane, Medicare, Medicine, Sevoflurane, Unconsciousness, Time, US, Benzodiazepine, Incidence, Methohexital, Fentanyl, COVID-19, Hospital, Bupivacaine, Brain, Etomidate, Analgesic, Anthem (company), Desflurane, Endo International, Drug, CAGR, Baxter International, Pharmaceutical industry, Propofol, Anesthesia, Ketamine, AbbVie, Growth, Pentobarbital

The "United States Anesthesia Drugs Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Anesthesia Drugs Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • United States Anesthesia Drugs Market will reach US$ 6.2 Billion by 2027 from $4.9 Billion in 2021, growing at a CAGR of 4%.
  • Covid-19 Impact on the United States Anesthesia Drugs Industry:
    The COVID-19 pandemic has significantly affected the United States anesthesia drugs market.
  • On the basis of type, United States anesthesia drugs market includes General Inhalation Anesthesia Drugs market, General Intravenous Anesthesia Drugs Market and Local Anesthesia Drugs Market.